<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="88362"><DrugName>adalimumab biosimilar, Zhejiang Hisun Pharmaceutical</DrugName><DrugNamesKey><Name id="42751034">adalimumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>adalimumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>anti-TNF-alpha mAb, Zhejiang Hisun Pharmaceutical</Value></Name><Name><Value>recombinant human tumor necrosis factor-alpha monoclonal antibody, Zhejiang Hisun Pharmaceutical</Value></Name><Name><Value>adalimumab biosimilar, Zhejiang Hisun Pharmaceutical</Value></Name><Name><Value>HS-016</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1019688" type="Company"><TargetEntity id="4295865361" type="organizationId">Zhejiang Hisun Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="398" type="ciIndication"><TargetEntity id="M45" type="ICD10"/><TargetEntity id="720.0" type="ICD9"/><TargetEntity id="10002556" type="MEDDRA"/><TargetEntity id="D013167" type="MeSH"/><TargetEntity id="-605402220" type="omicsDisease"/><TargetEntity id="752" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="381" type="Action"><TargetEntity id="663" type="Mechanism">TNF-alpha Antagonists</TargetEntity><TargetEntity id="1551" type="Mechanism">Anti-TNF-alpha</TargetEntity></SourceEntity><SourceEntity id="PTGT-07179" type="ciTarget"><TargetEntity id="202005724971243" type="siTarget">Tumor necrosis factor</TargetEntity><TargetEntity id="4487" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="PR">Pre-registration</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="398">Ankylosing spondylitis</Indication></IndicationsPrimary><ActionsPrimary><Action id="381">TNF alpha ligand inhibitor</Action><Action id="721">TNF binding agent</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="962">Biosimilar product</Technology><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><LastModificationDate>2019-02-26T08:56:59.000Z</LastModificationDate><ChangeDateLast>2019-02-26T00:00:00.000Z</ChangeDateLast><AddedDate>2013-11-13T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1019688" linkType="Company"&gt;Zhejiang Hisun Pharmaceutical&lt;/ulink&gt;  is developing HS-016, a biosimilar version of a recombinant human tumor necrosis factor-alpha monoclonal antibody (TNF-alpha mAb)  &lt;ulink linkID="14163" linkType="Drug"&gt;adalimumab&lt;/ulink&gt;,  for the potential subcutaneous treatment of ankylosing spondylitis,    rheumatoid arthritis and psoriasis [&lt;ulink linkID="1495541" linkType="Reference"&gt;1495541&lt;/ulink&gt;], [&lt;ulink linkID="1497221" linkType="Reference"&gt;1497221&lt;/ulink&gt;], [&lt;ulink linkID="2073742" linkType="Reference"&gt;2073742&lt;/ulink&gt;]. In September 2018, the launch application was accepted by China National Medical Products Administration[&lt;ulink linkID="2073742" linkType="Reference"&gt;2073742&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2013, the company was developing this product as a class 2 therapeutic biologic in China[&lt;ulink linkID="1495541" linkType="Reference"&gt;1495541&lt;/ulink&gt;]. By August 2018,   the company was preparing for filing for approval [&lt;ulink linkID="2067334" linkType="Reference"&gt;2067334&lt;/ulink&gt;]. In September 2018, an NDA application was accepted by China National Medical Products Administration[&lt;ulink linkID="2073742" linkType="Reference"&gt;2073742&lt;/ulink&gt;]. In February 2019, the NDA application was granted Priority Review in China [&lt;ulink linkID="2120201" linkType="Reference"&gt;2120201&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2016, a randomized, double-blind, parallel-group, phase III trial (&lt;ulink linkID="268843" linkType="Protocol"&gt;CTR20160398&lt;/ulink&gt;; HS016-III) was planned in China to compare the efficacy and safety of HS-016 to &lt;ulink linkID="14163" linkType="Drug"&gt;Hu                                             mira&lt;/ulink&gt; in adults (expected n = 603) with active ankylosing spondylitis [&lt;ulink linkID="1789574" linkType="Reference"&gt;1789574&lt;/ulink&gt;]. In September 2016, a phase III trial was initiated in China and recruitment was started[&lt;ulink linkID="1918616" linkType="Reference"&gt;1918616&lt;/ulink&gt;]. By February 2017, recruitment was still ongoing [&lt;ulink linkID="1918616" linkType="Reference"&gt;1918616&lt;/ulink&gt;]. By December 2017, recruitment had been finished; by  March 2018, the trial was ongoing [&lt;ulink linkID="2020187" linkType="Reference"&gt;2020187&lt;/ulink&gt;].  By August 2018, phase III development had been completed [&lt;ulink linkID="2067334" linkType="Reference"&gt;2067334&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, a randomized, double-blind, parallel-group, phase I trial (&lt;ulink linkID="268836" linkType="Protocol"&gt;CTR20160450&lt;/ulink&gt;; HS016-I), listing active ankylosing spondylitis as the indication, was initiated in China to evaluate the bioequivalence, PK characteristics, safety and immunogenicity of single sc administration of HS-016 to Humira in healthy male subjects (expected n = 136) [&lt;ulink linkID="1789572" linkType="Reference"&gt;1789572&lt;/ulink&gt;], [&lt;ulink linkID="1918615" linkType="Reference"&gt;1918615&lt;/ulink&gt;]. By December 2016, the trial was still ongoing [&lt;ulink linkID="1918614" linkType="Reference"&gt;1918614&lt;/ulink&gt;]. By December 2017, the trial had been completed [&lt;ulink linkID="2020187" linkType="Reference"&gt;2020187&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, a clinical trial application was filed in China [&lt;ulink linkID="1497221" linkType="Reference"&gt;1497221&lt;/ulink&gt;]. In January 2016, approval to conduct a clinical trial was obtained [&lt;ulink linkID="1746330" linkType="Reference"&gt;1746330&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2018, the project received funding from the Chinese government [&lt;ulink linkID="2106997" linkType="Reference"&gt;2106997&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2018-09-15T00:00:00.000Z</StatusDate><Source id="2073742" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-09-15T00:00:00.000Z</StatusDate><Source id="2073742" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2018-09-15T00:00:00.000Z</StatusDate><Source id="1918616" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2013-11-01T00:00:00.000Z</StatusDate><Source id="1497221" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="398">Ankylosing spondylitis</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1918615" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="398">Ankylosing spondylitis</Indication><AwardedIndication>Treatment of active ankylosing spondylitis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-14T00:00:00.000Z</MileStoneDate><Source id="2120201" type="OTHER"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="281">Psoriasis</Indication><AwardedIndication>Treatment of psoriasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-14T00:00:00.000Z</MileStoneDate><Source id="2120201" type="OTHER"/></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</OwnerCompany><Country id="CN">China</Country><Indication id="291">Rheumatoid arthritis</Indication><AwardedIndication>Treatment of rheumatoid arthritis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-02-14T00:00:00.000Z</MileStoneDate><Source id="2120201" type="OTHER"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03212"><Name>Tumor necrosis factor ligand</Name><SwissprotNumbers/></Target><Target id="PTGT-07179"><Name>TNF alpha ligand</Name><SwissprotNumbers><Swissprot>O35734</Swissprot><Swissprot>O77510</Swissprot><Swissprot>O77764</Swissprot><Swissprot>P01375</Swissprot><Swissprot>P04924</Swissprot><Swissprot>P06804</Swissprot><Swissprot>P13296</Swissprot><Swissprot>P16599</Swissprot><Swissprot>P19101</Swissprot><Swissprot>P23383</Swissprot><Swissprot>P23563</Swissprot><Swissprot>P29553</Swissprot><Swissprot>P33620</Swissprot><Swissprot>P36939</Swissprot><Swissprot>P48094</Swissprot><Swissprot>P51435</Swissprot><Swissprot>P51742</Swissprot><Swissprot>P51743</Swissprot><Swissprot>P59684</Swissprot><Swissprot>P59693</Swissprot><Swissprot>P59694</Swissprot><Swissprot>P59695</Swissprot><Swissprot>P79337</Swissprot><Swissprot>P79374</Swissprot><Swissprot>Q06599</Swissprot><Swissprot>Q19LH4</Swissprot><Swissprot>Q1G1A2</Swissprot><Swissprot>Q1WM27</Swissprot><Swissprot>Q2MH05</Swissprot><Swissprot>Q539C2</Swissprot><Swissprot>Q75N23</Swissprot><Swissprot>Q8HZD9</Swissprot><Swissprot>Q8JFG3</Swissprot><Swissprot>Q8MKG8</Swissprot><Swissprot>Q8WNR1</Swissprot><Swissprot>Q9BEA1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1019688">Zhejiang Hisun Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1057639">Chinese Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="252510" title="Chinese Government to award a grant to Zhejiang Hisun to develop etanercept, infliximab, adalimumab and tocilizumab biosimilars"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>